strate. Bosentan is a CYP3A4 and CYP2C9 substrate and a CYP3A4 inducer.
Bosutinib: (Major) Avoid coadministration of ribociclib with bosutinib, as the systemic exposure of bosutinib may be increased resulting an increase in bosutinib-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and bosutinib is a CYP3A4 substrate.
Brentuximab vedotin: (Moderate) Use caution if coadministration of ribociclib with brentuximab vedotin is necessary, as the systemic exposure of the microtubule disrupting agent of brentuximab vedotin, monomethyl auristatin E (MMAE), may be increased resulting in an increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor. In vitro data indicate that MMAE is primarily metabolized by CYP3A.
Brexpiprazole: (Moderate) Use caution if coadministration of ribociclib, a moderate CYP3A4 inhibitor, with brexpiprazole, a CYP3A4 substrate, is necessary, as the systemic exposure of brexpiprazole may be increased resulting in an increase in brexpiprazole-related adverse reactions. If brexpiprazole and ribociclib are coadministered with a moderate to strong inhibitor of CYP2D6, reduce the dose of brexpiprazole to one-quarter (25%) of the usual dose. A reduction of the brexpiprazole dose to 25% of the usual dose is also recommended in patients who are poor metabolizers of CYP2D6 and are receiving a moderate CYP3A4 inhibitor.
Brigatinib: (Moderate) Monitor for decreased efficacy of ribociclib if coadministration is necessary. Ribociclib is a CYP3A substrate and brigatinib induces CYP3A in vitro. Coadministration with a strong CYP3A4 inducer decreased the ribociclib AUC and Cmax by 89% and 81%, respectively, in healthy volunteers; brigatinib may also decrease ribociclib exposure.
Bromocriptine: (Major) When bromocriptine is used for diabetes, do not exceed a dose of 1.6 mg once daily during concomitant use of ribociclib. Use this combination with caution in patients receiving bromocriptine for other indications. Concurrent use may increase bromocriptine concentrations. Bromocriptine is extensively metabolized in the liver via CYP3A4; ribociclib is a moderate inhibitor of CYP3A4.
Brompheniramine; Dextromethorphan; Guaifenesin: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Brompheniramine; Guaifenesin; Hydrocodone: (Moderate) Use caution if coadministration of ribociclib with hydrocodone is necessary, as the systemic exposure of hydrocodone may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of hydrocodone if necessary. Ribociclib is a moderate CYP3A4 inhibitor and hydrocodone is a CYP3A4 substrate.
Brompheniramine; Hydrocodone; Pseudoephedrine: (Moderate) Use caution if coadministration of ribociclib with hydrocodone is necessary, as the systemic exposure of hydrocodone may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of hydrocodone if necessary. Ribociclib is a moderate CYP3A4 inhibitor and hydrocodone is a CYP3A4 substrate.
Budesonide: (Major) Avoid coadministration of ribociclib with systemic bud |
